Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMVP Health Care DMD Drug Therapy Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy N/A

    Duchenne Muscular Dystrophy Drug Therapy

    Customize your policy alerts

    Sign up for all MVP Health Care policy alerts

    Know when MVP Health Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and coverage criteria for corticosteroid, exon-skipping, and gene therapy drugs used to treat Duchenne muscular dystrophy across MVP commercial, Medicaid, and applicable product lines.

    Policy Summary
    PayerMVP Health Care
    PolicyDuchenne Muscular Dystrophy Drug Therapy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before prescribing Emflaza or Agamree under the pharmacy benefit.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6Drugs requiring prior authorization
    6 moInitial Emflaza or Agamree approval
    12 mo

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Maximum Emflaza or Agamree extension
    One-timeElevidys dosing
    4 yrMinimum Elevidys age
    45/51/53Exon-skipping targets

    Coverage Criteria

    Initial Therapy: Emflaza and Agamree

    Covered when ALL of the following criteria are met. Initial approval is for 6 months.

    ALL of the following

    • Diagnosis of Duchenne muscular dystrophy (DMD) confirmed by genetic testing.
    • Member is 2 years of age or older.
    • Prescribed by or in consultation with a provider who specializes in the treatment of DMD or neuromuscular disorders.
    • ONE of the following

      • Weight gain defined as at least a 10% increase in weight from baseline after 6 months of prednisone therapy.
      • Cushingoid appearance.
      • Severe psychiatric adverse effects, such as aggression, abnormal behavior, or mood swings, that would necessitate a prednisone dose reduction.

    Continuation Therapy: Emflaza and Agamree

    Extension requests for up to 12 months will be approved when the member demonstrates continued benefit from therapy, including at least one of the following.

    ONE of the following

    • Increase in muscle strength, pulmonary function tests, or timed function tests.
    • Decrease in adverse effects experienced while receiving prednisone.

    New York Medicaid: Exon-Skipping Therapies

    For New York Medicaid, pharmacy-benefit medications are covered and billed to the New York State Fee-for-Service (FFS) program. These medications include products obtained through a retail or specialty pharmacy, including self-administered injectable products, and are subject to FFS clinical criteria, including coverage, quantity limits, step therapy, and prior authorization. Pharmacy benefit information is available at https://www.emedny.org/info/fullform.pdf. Requests are reviewed when ALL of the following criteria are met based on New York State Department of Health Fee-for-Service criteria. Approval is for 6 months.

    ALL of the following

    • Member has a diagnosis of Duchenne muscular dystrophy (DMD).
    • Genetic testing confirms that the member's DMD gene mutation is amenable to exon 45, 51, or 53 skipping.
    • Documentation confirms a stable dose of corticosteroids before starting therapy, or provides a documented reason why the member is not receiving corticosteroids.
    • Documentation indicates kidney function testing was completed before starting therapy, except for eteplirsen.

    New York Medicaid: Elevidys

    For New York Medicaid, requests for Elevidys are reviewed when ALL of the following criteria are met based on New York State Department of Health Fee-for-Service criteria.

    ALL of the following

    • Member has a diagnosis of Duchenne muscular dystrophy (DMD).
    • Genetic testing confirms the DMD gene mutation.
    • Member is ambulatory.
    • Member is at least 4 years old.
    • Documentation confirms that the member does not have a deletion in exon 8 and/or exon 9 of the DMD gene.

    Elevidys

    Elevidys may be considered for coverage when ALL of the following criteria are met. Coverage is contingent on eligibility at the time of infusion.

    ALL of the following

    • Member is at least 4 years old.
    • Member has a confirmed diagnosis of Duchenne muscular dystrophy (DMD).
    • Genetic testing confirms the DMD gene mutation.
    • Member is ambulatory.
    • Documentation confirms that the member does not have a deletion in exon 8 and/or exon 9 of the DMD gene.
    • Member has anti-AAVrh74 total binding antibody titers <1:400.

    Age, dose, frequency of dosing, and/or duration of therapy outside FDA-approved package labeling are excluded from coverage.

    Combination therapy with other corticosteroids is excluded from coverage.

    Exondys 51 is excluded for all diagnoses, including Duchenne muscular dystrophy, because clinical benefit, including improved motor function, has not been demonstrated.

    Vyondys 53 is excluded for all diagnoses, including Duchenne muscular dystrophy, because clinical benefit has not been confirmed.

    Viltepso is excluded for all diagnoses, including Duchenne muscular dystrophy, because clinical benefit has not been confirmed.

    Amondys 45 is excluded for all diagnoses, including Duchenne muscular dystrophy, because clinical benefit has not been confirmed.

    Elevidys is excluded for non-ambulatory members with Duchenne muscular dystrophy because clinical benefit has not been confirmed.

    Medical Benefit Drugs and Operational Limits

    Drugs Requiring Prior Authorization under the Medical BenefitHCPCS
    J1428Exondys 51 (eteplirsen)
    J1429Vyondys 53 (golodirsen)
    J1427Viltepso (viltolarsen)
    J1426Amondys 45 (casimersen)
    J1413Elevidys (delandistrogene moxeparvovec-rokl)
    Prednisone-associated weight gain
    Qualifying adverse effectWeight gain of at least a 10% increase from baseline after 6 months of prednisone therapy
    Required prednisone trialMinimum 6-month trial before Emflaza or Agamree coverage
    DocumentationChart notes supporting the adverse effect must be submitted
    Elevidys anti-AAVrh74 antibody titer
    TestElevidys anti-AAVrh74 total binding antibody titer
    Required resultLess than 1:400
    Timing

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Pharmacy Benefit Prior Authorization Required

    Prior authorization is required for Emflaza (deflazacort) and Agamree when covered under the pharmacy benefit.

    • Emflaza (deflazacort)
    • Agamree
    Prior Authorization

    Medical Benefit Prior Authorization Required

    Prior authorization is required under the medical benefit for the listed exon-skipping and gene therapy products. Medicare Part D coverage may differ; refer to the MVP Medicare Part D formulary.

    • J1428 — Exondys 51 (eteplirsen)
    • J1429 — Vyondys 53 (golodirsen)
    • J1427 — Viltepso (viltolarsen)
    • J1426 — Amondys 45 (casimersen)
    • J1413 — Elevidys (delandistrogene moxeparvovec-rokl)

    Disease Background

    Duchenne muscular dystrophy is caused by a defective gene on the X chromosome that affects dystrophin production. Clinical onset commonly occurs between ages 2 and 3 and may involve muscle weakness, cardiomyopathy, conduction abnormalities, fractures, and scoliosis.

    Key Definitions

    Mutation amenable to exon skipping
    DefinitionA genetic variant in the DMD gene that can be targeted by exon-skipping therapy
    Targeted exonsExon 45, exon 51, or exon 53
    DocumentationGenetic testing must confirm that the member’s DMD mutation is amenable to exon 45, 51, or 53 skipping
    Ambulatory
    DefinitionA member able to walk
    Applicable therapyElevidys
    Coverage requirementAmbulatory status must be confirmed for Elevidys coverage

    Initial Therapy Criteria

    Emflaza and Agamree

    Covered when ALL of the following criteria are met.

    Emflaza or Agamree

    • Diagnosis of Duchenne muscular dystrophy confirmed by genetic testing.
    • Member is at least 2 years old.Age >=2 years
    • The prescription is from, or made in consultation with, a provider specializing in Duchenne muscular dystrophy or neuromuscular disorders.
    • The member has completed a minimum 6-month trial of prednisone.Prednisone trial >=6 months

    Continuation Therapy Criteria

    Emflaza and Agamree Continuation

    Extension requests up to 12 months will be approved when continued benefit is demonstrated.

    Continued clinical benefit from Emflaza or Agamree

    • Increase in muscle strength.
    • Improvement in pulmonary-function testing.
    • Improvement in timed-function testing.
    • Decrease in adverse effects experienced while receiving prednisone.

    Step Therapy Requirements

    StepTherapyRequirementDuration or exception
    1
    Emflaza or Agamree
    Complete a minimum 6-month trial of prednisone before coverage.
    Coverage may be considered sooner if the member develops a qualifying intolerable adverse effect, including at least 10% weight gain from baseline, Cushingoid appearance, or severe psychiatric adverse effects requiring prednisone dose reduction.
    StepTherapyRequirementException
    1
    Exondys 51, Vyondys 53, Amondys 45, or Viltepso
    Document a stable corticosteroid dose before starting therapy.
    A documented reason the member cannot take corticosteroids may be submitted instead.

    Approval Duration and Dosing Limits

    Emflaza and Agamree
    Initial approval6 months
    Applicable therapiesEmflaza and Agamree
    ExtensionsUp to 12 months when the member shows continued benefit to therapy
    Elevidys
    Dose frequencyOne-time dose
    Approval windowWithin 6 months
    Replacement requestsReplacement due to lost or damaged product is not covered

    Site of Care and Benefit Administration

    Billing Rule

    Hospital outpatient authorization

    For hospital outpatient administration of the listed medical-benefit drugs, obtain the required medical benefit prior authorization. The policy does not specify a more restrictive infusion setting.

    Policy Summary
    PayerMVP Health Care
    PolicyDuchenne Muscular Dystrophy Drug Therapy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before prescribing Emflaza or Agamree under the pharmacy benefit.
    SourceLink
    On This Page
    Coverage CriteriaMedical Benefit Drugs and Operational LimitsAuthorization, Documentation, and Denial RisksDisease BackgroundKey DefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaStep Therapy RequirementsApproval Duration and Dosing LimitsSite of Care and Benefit Administration
  1. Member is not concurrently being treated with another exon-skipping therapy for DMD.
  2. Member has anti-AAVrh74 total binding antibody titers <1:400.
  3. Documentation confirms liver function, platelet counts, and troponin-I assessment before starting therapy.
  4. Member is not concurrently being treated with another exon-skipping therapy for DMD.
  5. Documentation confirms liver function, platelet counts, and troponin-I assessment before starting therapy.
  6. Member is not concurrently being treated with another exon-skipping therapy for DMD.
  7. Documentation is required before starting therapy
    Initial Emflaza or Agamree approval
    Initial approval6 months
    Applicable therapiesEmflaza or Agamree
    Extension periodExtensions may be approved for up to 12 months when continued benefit is demonstrated
    Elevidys dosing
    Dose frequencyOne-time dose
    Approval windowWithin 6 months
    Infusion eligibilityCoverage is contingent on eligibility at the time of infusion
    Step Therapy

    Complete the Prednisone Trial

    Before requesting Emflaza or Agamree, document a minimum 6-month prednisone trial. Coverage requires at least one qualifying intolerable adverse effect after the trial, unless the record documents a qualifying reason the trial cannot be completed.

    • Weight gain of at least 10% from baseline after 6 months of prednisone therapy
    • Cushingoid appearance
    • Severe psychiatric effects, such as aggression, abnormal behavior, or mood swings requiring prednisone dose reduction
    Documentation Required

    Document the Corticosteroid Prerequisite

    For New York Medicaid requests for Exondys 51, Vyondys 53, Amondys 45, or Viltepso, submit documentation confirming a stable corticosteroid dose before therapy or a documented reason the member cannot receive corticosteroids.

    • Applies to New York State Fee-for-Service Medicaid clinical criteria
    • Pharmacy-benefit medications are subject to Medicaid coverage, quantity-limit, step-therapy, and prior-authorization requirements
    Documentation Required

    Document Emflaza or Agamree Eligibility

    Submit complete initial-therapy documentation for Emflaza or Agamree. The member must have genetically confirmed Duchenne muscular dystrophy, be at least 2 years old, and be treated by or in consultation with a DMD or neuromuscular-disorder specialist.

    • Genetic testing confirming DMD
    • At least 6 months of prednisone therapy
    • Chart notes supporting qualifying prednisone intolerance or inadequate tolerability: ≥10% weight gain, Cushingoid appearance, or severe psychiatric adverse effects
    Documentation Required

    Document Exon-Skipping Therapy Criteria

    For Exondys 51, Vyondys 53, Amondys 45, and Viltepso, submit all clinical documentation required for New York Medicaid review before requesting authorization.

    • DMD diagnosis
    • Genetic testing confirming a mutation amenable to exon 45, 51, or 53 skipping, as applicable
    • Stable corticosteroid dose or documented reason not to use corticosteroids
    • Baseline kidney-function testing before therapy, except for eteplirsen
    • No concurrent treatment with another exon-skipping therapy for DMD
    Documentation Required

    Document Elevidys Eligibility

    Elevidys requests require complete documentation of diagnosis, genetic findings, ambulatory status, age, deletion status, antibody titers, and required baseline laboratory assessments.

    • Confirmed DMD diagnosis and genetic testing confirming the DMD gene mutation
    • Member is ambulatory and at least 4 years old
    • No deletion in exon 8 and/or exon 9 of the DMD gene
    • Anti-AAVrh74 total binding antibody titers <1:400
    • Liver function, platelet counts, and troponin-I assessment before treatment
    • No concurrent exon-skipping therapy for DMD
    Documentation Required

    Document Continued Benefit

    For Emflaza or Agamree extension requests, submit evidence of continued benefit. Initial approval is for 6 months; extensions may be approved for up to 12 months when benefit is demonstrated.

    • Increased muscle strength, improved pulmonary function tests, or improved timed function tests
    • Decreased adverse effects compared with prednisone therapy
    Denial Risk

    Watch for Excluded Therapy Conditions

    Coverage is excluded when treatment is outside FDA-approved package labeling or when corticosteroids are used in combination with other corticosteroids.

    • Age, dose, dosing frequency, or duration outside FDA-approved labeling
    • Combination therapy with other corticosteroids
    Denial Risk

    Unconfirmed or Non-Ambulatory Uses Are Excluded

    Coverage is excluded for unconfirmed indications and for Elevidys treatment of non-ambulatory members because clinical benefit has not been confirmed for these uses.

    • Exondys 51, Vyondys 53, Viltepso, or Amondys 45 for diagnoses or uses lacking confirmed clinical benefit, including the excluded DMD indications stated in the policy
    • Elevidys for non-ambulatory members with DMD
    Denial Risk

    Elevidys Replacement and Infusion Eligibility

    Elevidys is a one-time dose approved within 6 months. Replacement requests for lost or damaged product are not covered, and the member must remain eligible at the time of infusion.

    • Do not submit replacement requests for lost or damaged Elevidys
    • Verify eligibility at the time of infusion
    Denial Risk

    Prevent Denials From Missing Medicaid Documentation

    Missing or incomplete Medicaid clinical documentation creates denial risk. Submit the applicable genetic, corticosteroid, laboratory, age, ambulatory-status, antibody-titer, and concurrent-therapy documentation with each request.

    • Genetic testing and mutation amenability or deletion-status documentation
    • Corticosteroid stability or documented contraindication/reason for nonuse
    • Required kidney, liver, platelet-count, and troponin-I testing
    • Age and ambulatory-status documentation for Elevidys
    • Anti-AAVrh74 antibody titer <1:400 for Elevidys
    • Confirmation that the member is not receiving another exon-skipping therapy
  8. At least one qualifying intolerable prednisone adverse effect

    • Weight gain of at least 10% from baseline after 6 months of prednisone therapy.Weight gain >=10% from baseline
    • Cushingoid appearance.
    • Severe psychiatric adverse effects, such as aggression, abnormal behavior, or mood swings, necessitating a prednisone dose reduction.
  9. Exondys 51, Vyondys 53, Amondys 45, and Viltepso

    New York Medicaid Fee-for-Service coverage is reviewed when ALL of the following criteria are met.

    Exondys 51, Vyondys 53, Amondys 45, or Viltepso

    • The member has a diagnosis of Duchenne muscular dystrophy.
    • Genetic testing confirms that the member's DMD gene mutation is amenable to exon 45, 51, or 53 skipping.
    • Documentation confirms a stable corticosteroid dose before starting therapy, or provides a documented reason the member cannot take corticosteroids.
    • Kidney-function testing is documented before starting therapy, except for eteplirsen.
    • The member is not concurrently receiving another exon-skipping therapy for Duchenne muscular dystrophy.

    Elevidys

    Covered when ALL of the following criteria are met.

    • The member is at least 4 years old.Age >=4 years
    • The member has a confirmed diagnosis of Duchenne muscular dystrophy.
    • Genetic testing confirms the DMD gene mutation.
    • The member is ambulatory.
    • Documentation confirms there is no deletion in exon 8 and/or exon 9 of the DMD gene.
    • Anti-AAVrh74 total binding antibody titers are below 1:400.Anti-AAVrh74 titer <1:400
    • Liver-function testing, platelet counts, and troponin-I assessment are documented before starting therapy.
    • The member is not concurrently receiving another exon-skipping therapy for Duchenne muscular dystrophy.
    Exondys 51, Vyondys 53, Amondys 45, and Viltepso
    Approval period6 months
    Applicable therapiesExondys 51, Vyondys 53, Amondys 45, and Viltepso
    Review basisNew York State Department of Health Fee-for-Service criteria